Spots Global Cancer Trial Database for molecular targeted therapy
Every month we try and update this database with for molecular targeted therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer | NCT02523495 | Neoplasms, Ther... | - | Huazhong University of Science and Technology | ||
| The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer | NCT02523495 | Neoplasms, Ther... | - | Huazhong University of Science and Technology | ||
| Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | NCT04642547 | Hepatocellular ... Molecular Targe... | Lenvatinib and ... | 18 Years - 75 Years | RenJi Hospital | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer | NCT05187208 | Epithelial Ovar... Ovarian Cancer Ovarian Cancer ... Ovarian Cancer ... | Niraparib | 20 Years - | Seoul National University Hospital | |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02766699 | Glioblastoma Astrocytoma, Gr... | EGFR(V)-EDV-Dox | 18 Years - | Engeneic Pty Limited | |
| Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | NCT05981157 | Nasopharyngeal ... | Anrotinib plus ... | 18 Years - 75 Years | Zhongshan People's Hospital, Guangdong, China | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | NCT05981157 | Nasopharyngeal ... | Anrotinib plus ... | 18 Years - 75 Years | Zhongshan People's Hospital, Guangdong, China | |
| Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | NCT02596828 | Pineoblastoma | Temozolomide Irinotecan Dasatinib Rapamycin | 0 Years - 25 Years | University of Regensburg | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | NCT04521153 | Hepatocellular ... Immunotherapy Molecular Targe... | Camrelizumab Apatinib Mesyla... TACE treatment Radical surgery | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. | NCT05768178 | Solid Tumor Haematological ... Melanoma Thyroid Cancer,... Ovarian Neoplas... Colorectal Neop... Laryngeal Neopl... Carcinoma, Non-... Glioma Multiple Myelom... Erdheim-Chester... Thyroid Carcino... | Vemurafenib Cobimetinib | 18 Years - | Cancer Research UK | |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) | NCT02766699 | Glioblastoma Astrocytoma, Gr... | EGFR(V)-EDV-Dox | 18 Years - | Engeneic Pty Limited | |
| Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma | NCT01467986 | Neuroblastoma R... | Dasatinib Rapamycin Irinotecan Temozolomide Irinotecan Temozolomide | - 25 Years | University of Regensburg | |
| Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy | NCT01652560 | Breast Cancer Bevacizumab Neoadjuvant Che... Molecular Targe... | bevacizumab | 18 Years - 75 Years | Xijing Hospital | |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. | NCT05770544 | Solid Tumor Haematological ... Malignancy Malignant Neopl... Lymphoprolifera... Neoplasms by Hi... Neoplasms by Si... Cancer Brain Neoplasms Melanoma Glioma | Entrectinib | - | Cancer Research UK | |
| Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | NCT04586088 | Nasopharyngeal ... Recurrent Nasop... Metastatic Naso... Chemotherapy Ef... Immunotherapy Molecular Targe... | Apatinib plus C... | 18 Years - 70 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
